Additionally, the pathological staging analysis via GEPIA2.0 indicated that TIGD1 expression varied significantly across different cancer stages in ACC, COAD, KICH, LIHC, OV, and THCA (Figure 3b), supporting its potential role in tumor progression. This evidence concerns the gene TIGD1 and adrenal cortex carcinoma.